Eagle Bay Advisors’s Viking Therapeutics VKTX Stock Holding History

Eagle Bay Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,281	Closed	-$91.8K	–	915
2024 Q4	$91.8K	Buy	+2,281	New	+$130K	0.06%	226

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eagle Bay Advisors's VKTX Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 2,281 shares — an estimated $91.8K sold.

Eagle Bay Advisors first reported a position in VKTX in Q4 2024 and held it in 1 quarter. The position peaked at $91.8K in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Eagle Bay Advisors reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 2,281 Viking Therapeutics shares in Q1 2025, an estimated $91.8K.
Eagle Bay Advisors first reported a position in Viking Therapeutics in Q4 2024 and held it in 1 quarter.
Eagle Bay Advisors's Viking Therapeutics position peaked at $91.8K in Q4 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.